PARP1 and neoplasm: The low toxicity of PARP inhibitors, as well as the loss of heterozygosity in germline HRD mutations or somatic mutations in cancer cells, but not surrounding tissues, makes PARP inhibitor lethality with HRD attractive due to its tumor-selective effects.